Hogg RS, Heath KV, Yip B.
et al. Improved survival among HIV-infected individuals following initiation
of antiretroviral therapy. JAMA.1998;279:450-454.
Mocroft A, Katlama C, Johnson AM.
et al. AIDS across Europe, 1994-98. Lancet.2000;356:291-296.
Palella Jr FJ, Delaney KM, Moorman AC.
et al. Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Carpenter CC, Cooper DA, Fischl MA.
et al. Antiretroviral therapy in adults. JAMA.2000;283:381-390.
Staszewski S, Morales-Ramirez J, Tashima KT.
et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir,
and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection
in adults. N Engl J Med.1999;341:1865-1873.
Staszewski S, Keiser P, Montaner J.
et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in
antiretroviral-naive HIV-infected adults. JAMA.2001;285:1155-1163.
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Deeks SG, Hecht FM, Swanson M.
et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in
an urban AIDS clinic. AIDS.1999;13:F35-F43.
Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic. Ann Intern Med.1999;131:81-87.
Paterson DL, Swindells S, Mohr J.
et al. Adherence to protease inhibitor therapy and outcomes in patients with
HIV infection. Ann Intern Med.2000;133:21-30.
Martinez E, Mocroft A, Garcia-Viejo MA.
et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease
Montaner JS, Mellors JW. Antiretroviral therapy for previously treated patients. N Engl J Med.2001;345:452-455.
Hirsch MS, Brun-Vezinet F, D'Aquila RT.
et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA.2000;283:2417-2426.
Gulick RM, Hu XJ, Fiscus SA.
et al. Randomized study of saquinavir with ritonavir or nelfinavir together
with delavirdine, adefovir, or both in human immunodeficiency virus-infected
adults with virologic failure on indinavir. J Infect Dis.2000;182:1375-1384.
Falloon J, Piscitelli S, Vogel S.
et al. Combination therapy with amprenavir, abacavir, and efavirenz in human
immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor
regimen. Clin Infect Dis.2000;30:313-318.
Falloon J, Ait-Khaled M, Thomas DA.
et al. HIV-1 genotype and phenotype correlate with virological response to
abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS.2002;16:387-396.
Hammer S, Demeter L, DeGruttola V.
et al. Relationship of phenotypic and genotypic resistance profiles to virological
outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil
in patients with virological failure receiving indinavir (ACTG 372). From: 3rd International Workshop on HIV Drug Resistance and Treatment
Strategies; June 23-26, 1999; San Diego, Calif. Abstract No. 64.
Tebas P, Patick AK, Kane EM.
et al. Virologic responses to a ritonavir-saquinavir-containing regimen in
patients who had previously failed nelfinavir. AIDS.1999;13:F23-F28.
Durant J, Clevenbergh P, Halfon P.
et al. Drug-resistance genotyping in HIV-1 therapy. Lancet.1999;353:2195-2199.
Baxter JD, Mayers DL, Wentworth DN.
et al. A randomized study of antiretroviral management based on plasma genotypic
antiretroviral resistance testing in patients failing therapy. AIDS.2000;14:F83-F93.
Cohen CJ, Hunt S, Sension M.
et al. A randomized trial assessing the impact of phenotypic resistance testing
on antiretroviral therapy. AIDS.2002;16:579-588.
Tural C, Ruiz L, Holtzer C.
et al. Clinical utility of HIV-1 genotyping and expert advice. AIDS.2002;16:209-218.
Cingolani A, Antinori A, Rizzo MG.
et al. Usefulness of monitoring HIV drug resistance and adherence in individuals
failing highly active antiretroviral therapy. AIDS.2002;16:369-379.
Cameron DW, Japour AJ, Xu Y.
et al. Ritonavir and saquinavir combination therapy for the treatment of HIV
Raines CP, Flexner C, Sun E.
et al. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir
combination therapy administered for 48 weeks. J Acquir Immune Defic Syndr.2000;25:322-328.
Hugen PW, Burger DM, ter Hofstede HJ.
et al. Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr.2000;25:236-245.
Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clin Pharmacokinet.1998;35:275-291.
Kempf DJ, Marsh KC, Kumar G.
et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency
virus protease by coadministration with ritonavir. Antimicrob Agents Chemother.1997;41:654-660.
Sham HL, Kempf DJ, Molla A.
et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus
protease. Antimicrob Agents Chemother.1998;42:3218-3224.
Benson CA, Deeks SG, Brun SC.
et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus
nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency
virus type 1-infected protease inhibitor-experienced patients. J Infect Dis.2002;185:599-607.
Eron JJ, Haubrich R, Lang W.
et al. A phase II trial of dual protease inhibitor therapy. J Acquir Immune Defic Syndr.2001;26:458-461.
Fung HB, Kirschenbaum HL, Hameed R. Amprenavir. Clin Ther.2000;22:549-572.
Adkins JC, Faulds D. Amprenavir. Drugs.1998;55:837-844.
Schmidt B, Korn K, Moschik B.
et al. Low level of cross-resistance to amprenavir (141W94) in samples from
patients pretreated with other protease inhibitors. Antimicrob Agents Chemother.2000;44:3213-3216.
Division of AIDS Table for Grading Severity of Adult Adverse
Experiences. Rockville, Md: National Institute of Allergy and Infectious Diseases;
Raboud JM, Montaner JS, Conway B.
et al. Suppression of plasma viral load below 20 copies/ml is required to
achieve a long-term response to therapy. AIDS.1998;12:1619-1624.
Kempf DJ, Rode RA, Xu Y.
et al. The duration of viral suppression during protease inhibitor therapy
for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS.1998;12:F9-F14.
Demeter LM, Hughes MD, Coombs RW.
et al. Predictors of virologic and clinical outcomes in HIV-1-infected patients
receiving concurrent treatment with indinavir, zidovudine, and lamivudine. Ann Intern Med.2001;135:954-964.
Polis MA, Sidorov IA, Yoder C.
et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week
after start of antiretroviral treatment and longer-term efficacy. Lancet.2001;358:1760-1765.
Marschner IC, Collier AC, Coombs RW.
et al. Use of changes in plasma levels of human immunodeficiency virus type
1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis.1998;177:40-47.
Flexner C. HIV-protease inhibitors. N Engl J Med.1998;338:1281-1292.
Fletcher CV, Acosta EP, Cheng H.
et al. Competing drug-drug interactions among multidrug antiretroviral regimens
used in the treatment of HIV-infected subjects. AIDS.2000;14:2495-2501.
Havlir DV, Bassett R, Levitan D.
et al. Prevalence and predictive value of intermittent viremia with combination
HIV therapy. JAMA.2001;286:171-179.
Condra JH, Schleif WA, Blahy OM.
et al. In vivo emergence of HIV-1 variants resistant to multiple protease
Condra JH, Holder DJ, Schleif WA.
et al. Genetic correlates of in vivo viral resistance to indinavir, a human
immunodeficiency virus type 1 protease inhibitor. J Virol.1996;70:8270-8276.
Molla A, Korneyeva M, Gao Q.
et al. Ordered accumulation of mutations in HIV protease confers resistance
to ritonavir. Nat Med.1996;2:760-766.
Petropoulos CJ, Parkin NT, Limoli KL.
et al. A novel phenotypic drug susceptibility assay for human immunodeficiency
virus type 1. Antimicrob Agents Chemother.2000;44:920-928.
Haubrich R, Whitcomb J, Keiser P.
et al. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity
is common and improves short term virologic response. Antivir Ther.2000;5(suppl 3):S68.
Shulman N, Zolopa AR, Passaro D.
et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase
inhibitors in treatment-experienced HIV-infected patients. AIDS.2001;15:1125-1132.
Harrigan PR, Montaner JS, Wegner SA.
et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated
Buckley J, James I. Linear regression with censored data. Biometrika.1979;66:429-436.
DeGruttola V, Dix L, D'Aquila R.
et al. The relation between baseline HIV drug resistance and response to antiretroviral
therapy. Antivir Ther.2000;5:41-48.
Zhang J, Yu KF. What's the relative risk? a method of correcting the odds ratio in
cohort studies of common outcomes. JAMA.1998;280:1690-1691.
Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir
and adefovir. Clin Pharmacokinet.1999;36:127-143.
Villani P, Regazzi MB, Castelli F.
et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy
with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol.1999;48:712-715.
Vanhove GF, Gries JM, Verotta D.
et al. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine
in combination therapy. Antimicrob Agents Chemother.1997;41:2433-2438.
Zhou XJ, Havlir DV, Richman DD.
et al. Plasma population pharmacokinetics and penetration into cerebrospinal
fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected
Jackson KA, Rosenbaum SE, Kerr BM.
et al. A population pharmacokinetic analysis of nelfinavir mesylate in human
immunodeficiency virus-infected patients enrolled in a phase III clinical
trial. Antimicrob Agents Chemother.2000;44:1832-1837.
Bacheler L, Jeffrey S, Hanna G.
et al. Genotypic correlates of phenotypic resistance to efavirenz in virus
isolates from patients failing nonnucleoside reverse transcriptase inhibitor
therapy. J Virol.2001;75:4999-5008.
Saag MS, Sonnerborg A, Torres RA.
et al. Antiretroviral effect and safety of abacavir alone and in combination
with zidovudine in HIV-infected adults. AIDS.1998;12:F203-F209.
Katlama C, Clotet B, Plettenberg A.
et al. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced
Lanier E, Hellmann N, Scott J.
et al. Determination of a clinically relevant phenotypic resistance "cut-off"
for abacavir using the PhenoSense assay. From: 8th Conference on Retroviruses and Opportunistic Infections;
February 4-8, 2001; Chicago, Ill. Abstract No. 254.
Briones C, Soriano V, Barreiro P.
et al. Can early failure with nevirapine (NVP)-based regimens be rescued by
replacing NVP with efavirenz. From: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
September 17-20, 2000; Toronto, Ontario. Abstract No. 478.
Kahn J, Lagakos S, Wulfsohn M.
et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. JAMA.1999;282:2305-2312.
Mellors JW. Adefovir for the treatment of HIV infection. JAMA.1999;282:2355-2356.
Deeks SG, Barditch-Crovo P, Lietman PS.
et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous
9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency
virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother.1998;42:2380-2384.
Schooley R, Myers R, Ruane P.
et al. Tenofovir disoproxil fumarate (TDF) for the treatment of antiviral
experienced patients. From: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
September 17-20, 2000; Toronto, Ontario. Abstract No. 692.
Decker CJ, Laitinen LM, Bridson GW.
et al. Metabolism of amprenavir in liver microsomes. J Pharm Sci.1998;87:803-807.
Sadler BM, Gillotin C, Lou Y.
et al. Pharmacokinetic study of human immunodeficiency virus protease inhibitors
used in combination with amprenavir. Antimicrob Agents Chemother.2001;45:3663-3668.
Barry M, Mulcahy F, Merry C.
et al. Pharmacokinetics and potential interactions amongst antiretroviral
agents used to treat patients with HIV infection. Clin Pharmacokinet.1999;36:289-304.
Montaner JS, Harrigan PR, Jahnke N.
et al. Multiple drug rescue therapy for HIV-infected individuals with prior
virologic failure to multiple regimens. AIDS.2001;15:61-69.
Miller V, Sabin C, Hertogs K.
et al. Virological and immunological effects of treatment interruptions in
HIV-1 infected patients with treatment failure. AIDS.2000;14:2857-2867.
Deeks SG, Wrin T, Liegler T.
et al. Virologic and immunologic consequences of discontinuing combination
antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med.2001;344:472-480.
Rutschmann OT, Vernazza PL, Bucher HC.
et al. Long-term hydroxyurea in combination with didanosine and stavudine
for the treatment of HIV-1 infection. AIDS.2000;14:2145-2151.
Coull JJ, Turner D, Melby T.
et al. A pilot study of the use of mycophenolate mofetil as a component of
therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr.2001;26:423-434.
Becker S, Brun S, Bertz R.
et al. ABT-378/ritonavir and efavirenz. From: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
September 17-20, 2000; Toronto, Ontario. Abstract No. 697.